Patents Assigned to Connexios Life Sciences Pvt. Ltd.
  • Substituted bicyclic heteroaryl compounds as RXR agonists
    Patent number: 9862713
    Abstract: The present invention relates to certain substituted bicyclic compounds that are agonists of RXR and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 9, 2018
    Assignee: CONNEXIOS LIFE SCIENCES PVT. LTD.
    Inventors: Madhavan Gurram Ranga, Jagannath Rao, Chandra Sekhar Gudla
  • Cyclic amide derivatives as inhibitors of 11-?-hydroxysteroid dehydrogenase and uses thereof
    Patent number: 9453014
    Abstract: The present invention relates amide compounds of formula (I): wherein R1, R1a, Ar, A, B, W1, W2, D, a, b, and c are defined herein, and pharmaceutical acceptable salts thereof. These compounds have the ability to inhibit 11-?-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: September 27, 2016
    Assignee: Connexios Life Sciences Pvt. Ltd.
    Inventors: Jagannath Madanahalli Ranganath Rao, Uppala Venkatesham, Jenson George, George Fernand, Sivanageswara Rao Doppalapudi, G R Madhavan, Nagarajan Arumugam, Mohammed Ansari, K Murugavel, Jidugu Pradeep, Sulthan Allavuddeen, K Vijayaramalingam, Hampelingaiah Shiva Prasad, Augustine Michael Raj, S Gnanavel, Ramamoorthy Kottamalai, Naresh M P S Babu, Bommegowda Yadaganahalli Kenchegowda
  • Derivatives of aza adamantane and uses thereof
    Patent number: 9303016
    Abstract: The present invention relates to certain amide derivatives that have the ability to inhibit 11-?-hydroxysteroid dehydrogenase type 1 (11?-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: April 5, 2016
    Assignee: CONNEXIOS LIFE SCIENCES PVT. LTD.
    Inventors: Jagannath Madanahalli Ranganath Rao, Uppala Venkatesham, Sivanageswara Rao Doppalapudi, Bommegowda Yadaganahalli Kenchegowda, George Fernand, Jenson George, G R Madhavan, Gorle Paidapu Naidu, V. S. Naga Rajesh Kadambari, S Jagannath, R Manivannan, T Senthil Kumar, B Siva Senthil Kumar, Rayi Mallikarjuna
  • Agonists of GPR40
    Patent number: 9278915
    Abstract: The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 8, 2016
    Assignee: CONNEXIOS LIFE SCIENCES PVT LTD
    Inventors: Jagannath Madanahalli Ranganath Rao, Nagarajan Arumugam, Mohd Mudabbir Ansari, Chandrasekhar Gudla, Shanmugam Pachiyappan, Manivannan Ramalingam, Jenson George, George Fernanda Arul, Kenchegowda Bommegowda, Y, Sathesh Kumar Angupillai, Ramamoorthy Kottamalai, Pradeep Jidugu, Shivanageshwara Rao, D
  • Use of TAK1 Inhibitor to Achieve Glycemic Control in Mammals
    Publication number: 20140154263
    Abstract: The present invention relates to use of inhibitors of TAK-1 for the production of pharmaceutical agents to achieve glycemic control in mammals and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 5, 2014
    Applicant: Connexios Life Sciences Pvt. Ltd.
    Inventors: Anup Mammen Oommen, Mahesh Kumar Verma, Urvashi Bahadur, Swapnika Ramu